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Inhibition of bile acid (BA) transport may contribute to the
hepatotoxicity of troglitazone (TRO), a peroxisome proliferator–
activated receptor gamma agonist. Typically, studies use taur-
ocholic acid (TCA) as a model substrate to investigate effects of
xenobiotics on BA disposition. However, TRO may differentially
affect the transport of individual BAs, potentially causing
hepatocyte accumulation of more cytotoxic BAs. The effects of
TRO on the disposition of [14C]-labeled chenodeoxycholic acid
([14C]CDCA), an unconjugated cytotoxic BA, were determined
in suspended hepatocytes and sandwich-cultured hepatocytes
(SCH) from rats. (E)-3-[[[3-[2-(7-chloro-2-quinolinyl)ethenyl]-
phenyl][[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]-propanoic
acid (MK571), a multidrug resistance–associated protein (MRP)
inhibitor, was included to evaluate involvement of MRPs in CDCA
disposition. Accumulation in cells 1 bile of total [14C]CDCA
species in SCH was sixfold greater than [3H]TCA and unaffected
by 1 and 10mM TRO; 100mM TRO and 50mM MK571 ablated
biliary excretion and significantly increased intracellular accumu-
lation of total [14C]CDCA species. Results were similar in Mrp2-
deficient TR2 rat hepatocytes. Liquid chromatography-tandem
mass spectrometry (LC-MS/MS) analysis revealed that taurine- and
glycine-conjugated CDCA, in addition to unconjugated CDCA,
accumulated in hepatocytes during the 10-min incubation.
In suspended rat hepatocytes, initial [14C]CDCA uptake was
primarily Na1-independent, whereas initial [3H]TCA uptake was
primarily Na1-dependent; TRO and MK571 decreased [14C]CDCA
uptake to a lesser extent than [3H]TCA. Unexpectedly, MK571
inhibited Na1-taurocholate cotransporting polypeptide and bile salt
export pump. Differential effects on uptake and efflux of individual
BAs may contribute to TRO hepatotoxicity. Although TCA is the
prototypic BA used to investigate the effects of xenobiotics on BA
transport, it may not be reflective of other BAs.
Key Words: troglitazone; bile acids; hepatotoxicity; transport;
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Troglitazone (TRO) is a peroxisome proliferator–activated
receptor gamma agonist used clinically to treat noninsulin-
dependent type II diabetes until it was removed from the
market following a number of cases of severe idiosyncratic
hepapotoxicity. Much research has focused on determining the
mechanisms of TRO-mediated hepatotoxicity. One hypothesis is
that TRO inhibits hepatic bile acid (BA) transport; inhibition of
the bile salt export pump (BSEP) may cause intracellular
accumulation of BAs (reviewed in Masubuchi, 2006) and
subsequent toxicity due to detergent effects (Delzenne et al.,
1992; Pauli-Magnus et al., 2005). Impaired BSEP function is a
significant medical issue (reviewed in Pauli-Magnus et al., 2010);
however, drug-mediated inhibition of hepatic BA transport as a
mechanism of drug-induced liver injury is poorly understood.
Normally, BA disposition is tightly controlled, and hepatic BA
concentrations are governed by the rate of synthesis and by
basolateral (sinusoidal) and apical (canalicular) transport proteins.
On the basolateral membrane, the Naþ-taurocholate cotransport-
ing polypeptide (NTCP) mediates Naþ-dependent uptake of BAs,
whereas organic anion transporting polypeptide (OATP) isoforms
mediate Naþ-independent uptake of BAs, organic anions, some
organic cations, and neutral species (Trauner and Boyer, 2003).
On the apical membrane, BSEP is the major canalicular transport
protein that mediates biliary excretion of monomeric BAs,
whereas multidrug resistance–associated protein (MRP) 2
(MRP2/Mrp2) transports divalent BAs into the bile canaliculi
(Kullak-Ublick et al., 2000). Together, NTCP and BSEP represent
the major transport proteins responsible for the vectorial transport
of BAs from blood to bile. The basolateral efflux transporters,
MRP3, MRP4, and the organic solute transporter, OSTa/b, also
may be involved in the excretion of BAs from hepatocytes back
into the blood under cholestatic conditions (reviewed in Borst
et al., 2007; Soroka et al., 2010).
Taurocholic acid (TCA) is the taurine conjugate of the
primary BA cholic acid (CA) that is present in both rats and
humans. TCA is utilized commonly as a prototypic BA to
study the effect of xenobiotics and drugs, including TRO, on
BA transport both in vivo and in vitro. TRO caused the
accumulation of [14C]TCA in rat liver tissue (Funk et al., 2001b)
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and inhibited Bsep-mediated TCA transport in rat canalicular
membrane vesicles (Funk et al., 2001a) and in membrane
vesicles from Sf9 cells overexpressing Bsep from different
species (Kis et al., 2009). TRO inhibited TCA uptake and biliary
excretion in primary rat sandwich-cultured hepatocytes (SCH)
(Kemp et al., 2005) and inhibited TCA transport in both
basolateral and canalicular rat liver membrane vesicles (Snow
and Moseley, 2006). Studies by our group in human SCH
showed that TRO decreased TCA biliary excretion in a
concentration-dependent manner, consistent with BSEP
inhibition; Naþ-dependent initial uptake of TCA also was
inhibited in rat and human suspended hepatocytes (Marion et al.,
2007). TRO also caused intracellular retention of preloaded
[3H]TCA in human hepatocytes (Jemnitz et al., 2010).
BAs perform important physiological roles but are cytotoxic
and may cause mitochondrial dysfunction and trigger apoptosis
or necrosis if they accumulate to high intracellular concen-
trations. The hydrophobicity of individual BAs is inversely
proportional to the number and orientation of hydroxyl groups
on the steroid nucleus and is predictive of toxicity (reviewed in
Thomas et al., 2008). Individual BAs also have different
affinities for some BA transporters (Byrne et al., 2002; Gerloff
et al., 1998; Noe et al., 2001); thus, perturbation of BA
transport resulting in increased intracellular BAs may cause a
disproportionate accumulation of more cytotoxic BAs through
competition for transport.
The primary BA chenodeoxycholic acid (CDCA) comprises
an estimated 10.5% (Tagliacozzi et al., 2003) to 37% (McRae
et al., 2010) of the BAs in human plasma compared with 3%
(Tagliacozzi et al., 2003) to 3.6% (McRae et al., 2010) for TCA.
CDCA is more cytotoxic to hepatocytes than TCA (Miyazaki
et al., 1984), and concentrations in human liver can reportedly
increase 20-fold following extrahepatic biliary obstruction
(Greim et al., 1973). Hepatic uptake of CDCA reportedly
involves both Naþ-dependent (NTCP-mediated) and Naþ-
independent (i.e., OATP1B1 and OATP1B3) transport mech-
anisms (Maglova et al., 1995; Van Dyke et al., 1982);
OATP1B1 and OATP1B3 also can transport a fluorescent
CDCA analog (Yamaguchi et al., 2006). The present study
compared the effects of TRO on the disposition of CDCA versus
TCA in rat SCH and suspended hepatocytes. Experiments were
designed to determine whether TRO differentially affects the
hepatobiliary disposition of individual BAs resulting in greater
intracellular accumulation of CDCA compared with TCA, and to
examine the mechanism(s) of potential alterations. (E)-3-[[[3-[2-
(7-chloro-2-quinolinyl)ethenyl]phenyl][[3-(dimethylamino)-
3-oxopropyl]thio]methyl]thio]-propanoic acid (MK571), an MRP
inhibitor, was included to investigate the potential involvement
of MRPs in CDCA and TCA hepatobiliary disposition.
MATERIALS AND METHODS
Chemicals. [14C]CDCA (50 mCi/mmol; purity >97%) and [14C]inulin
(2.8 mCi/g; purity >97%) were purchased from American Radiolabeled
Chemicals, Inc. (St Louis, MO), and [3H]TCA (5 Ci/mmol; purity >97%) was
purchased from Perkin Elmer (Waltham, MA). TRO was purchased from
Biomol (Plymouth Meeting, PA). MK571 sodium salt was obtained from
Cayman Chemical (Ann Arbor, MI). Dexamethasone, Hanks’ balanced salt
solution (HBSS) premix, and HBSS modified (without calcium chloride,
magnesium sulfate, phenol red, and sodium bicarbonate) premix were
purchased from Sigma-Aldrich (St Louis, MO). Collagenase (type I, class I)
was obtained from Worthington Biochemical (Freehold, NJ), and dimethyl
sulfoxide (DMSO) was purchased from Fisher Scientific (Fairlawn, NJ).
GIBCO brand fetal bovine serum, recombinant human insulin, and Dulbecco’s
modified Eagle’s medium (DMEM) were purchased from Invitrogen (Carlsbad,
CA). ITS (insulin, transferrin, and selenium) Universal Culture Supplement
Premix and Matrigel Basement Membrane Matrix were obtained from BD
Biosciences (Palo Alto, CA). All other chemicals and reagents were of
analytical grade and were readily available from commercial sources.
Hepatocyte isolation and culture. Hepatocytes were isolated from wild-
type (WT) male Wistar rats (250–300 g; Charles River Laboratories, Inc.,
Raleigh, NC) or male Mrp2-deficient TR rats (250–300 g; in-house colony)
using a two-step collagenase perfusion method previously described
(LeCluyse et al., 1996). Rats were maintained on a 12-h light/dark cycle
with free access to water and standard rodent chow and allowed to acclimate
for at least 5 days before experimentation. The Institutional Animal Care and
Use Committee of the University of North Carolina at Chapel Hill approved
all procedures.
Hepatocytes were seeded at a density of 1.75 3 106 cells per well on six-
well BioCoat plates with collagen type I substratum in 1.5 ml DMEM
supplemented with 5% (vol/vol) fetal bovine serum, 10lM insulin, 1lM
dexamethasone, 2mM L-glutamine, 1% (vol/vol) Minimum Essential Medium
(MEM) nonessential amino acids, 100 U penicillin G sodium, and 100 lg
streptomycin sulfate. Cells were incubated at 37C in a humidified incubator
and allowed to attach for 2 h, after which time the medium was aspirated to
remove unattached cells and replaced with fresh medium. Twenty-four hours
later, on day 1 of culture, hepatocytes were overlaid with BD Matrigel
basement membrane matrix at a concentration of 0.25 mg/ml in ice-cold
DMEM supplemented with 1% (vol/vol) ITS þ premix, 0.1lM dexametha-
sone, 2mM l-glutamine, 1% (vol/vol) MEM nonessential amino acids, 100 U
penicillin G sodium, and 100 lg streptomycin sulfate. Cells were cultured for
three additional days to allow for the formation of canalicular networks
between cells. Culture medium was replaced daily.
Accumulation of [14C]CDCA and [3H]TCA in WTand TR rat SCH. On
day 4 of culture, hepatocytes were rinsed three times (20 s per each rinse) with
2 ml per well of warm standard HBSS with Ca2þ (three wells) or HBSS without
Ca2þ (three wells). Following the washes, 2 ml of warm HBSS with or without
Ca2þ were added, and cells were incubated at 37C for 10 min. Incubation of
SCH with Ca2þ-containing HBSS maintains the tight junctions between cells,
and the bile canalicular structures formed between cells remain intact.
Incubation of cells in Ca2þ-free HBSS disrupts the tight junctions, allowing
the contents of the canaliculi to be washed away. After incubation, the HBSS
was double aspirated from each well and 1.5 ml of dosing solution consisting of
HBSS with Ca2þ, substrate (1lM unlabeled CDCA plus 0.2lM [14C]CDCA or
1lM TCA plus trace [3H]TCA), or inhibitor (specified concentrations of TRO
or MK571 or vehicle [0.1% (vol/vol) DMSO]) were added. Cells were
incubated at 37C for 10 min. Following incubation, the dosing solution was
aspirated from the cells, and uptake was stopped by rinsing cells three times for
20 s each with 2 ml ice-cold HBSS with Ca2þ per wash. After washing, the
HBSS was aspirated and 1 ml of lysis buffer (0.5% [vol/vol] Triton X-100 in
PBS) was added to each well, and plates were shaken on a rotating plate shaker
for 20 min. Aliquots (500 ll) of sample and 100 ll aliquots of dosing solution
were collected for quantification of radioactivity by liquid scintillation
counting; 500 ll aliquots were reserved for protein quantification using the
Pierce BCA Protein Assay Kit (Thermo Scientific, Rockford, IL). Accumu-
lation of [14C]CDCA and [3H]TCA in BioCoat plates without cells was
subtracted to correct for nonspecific binding to the collagen substratum.
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Temperature-dependent accumulation of [14C]CDCA and [3H]TCA in
WT rat SCH. Accumulation in WT rat SCH of [14C]CDCA and [3H]TCA in
the presence of vehicle was measured at 37C using the above method.
Accumulation at 4C was carried out using the same method, except that all
reagents were kept at 4C, and all incubations were performed on ice.
Measurement of taurine- and glycine-conjugated CDCA species in WT
rat SCH. In order to determine the extent of CDCA metabolism to taurine or
glycine conjugates (TCDCA or GCDCA, respectively) during the 10-min
incubation in the accumulation studies, WT rat SCH were treated using the above
method for measuring accumulation of CDCA at 37C, except that the dosing
solution contained either vehicle (0.1% DMSO) or 1lM unlabeled CDCA only.
Following the final washes, wells were aspirated and plates were stored at70C
until analysis by liquid chromatography-tandem mass spectrometry (LC-MS/
MS) for TCDCA and GCDCA, as well as for the rodent-specific BAs
tauromuricholic acid (TMCA) and glycomuricholic acid (GMCA), which are
metabolites of CDCA. CDCA, TCDCA, and GCDCA were measured using
standard curves prepared with stable isotope equivalents; TMCA and GMCA
were estimated from standard curves for TCA and glycocholic acid (GCA). Ten
microliters of d4-TCDCA, d4-GCDCA, d8-TCA, and d4-GCA solutions in
methanol were added to previously frozen untreated rat SCH plates to yield a final
concentration of 0.5–100 pmol per well (0.5–200 pmol per well for TCA) as
standards. Lysis solution (750 ll; 70:30 [vol/vol] methanol:water containing 19
pmol per well d4 TCA as an internal standard) was added to each well of study
plates and to the plates containing standards. Plates were shaken on a rotating
plate shaker at a speed of 500 rpm for 15 min. The total contact time of the lysis
solution with cells, prior to filtration, was ~20 to 30 min. The cell lysates were
transferred to a Whatman 96-well Unifilter Plate (Whatman, Florham Park, NJ)
with 25 lm melt blown polypropylene over 0.45 lm polypropylene membrane.
Lysate was filtered into a Greiner 96-well Deepwell Plate by centrifugation at
2000 3 g for 5 min. Filtrate was evaporated to dryness under nitrogen gas,
reconstituted in 200 ll of sample diluent (60:40 [vol/vol] methanol:10mM
ammonium acetate [native pH]), and mixed for 15 min on the plate shaker at 500
rpm. The reconstituted samples were transferred to a Whatman 96-well Unifilter
Plate with 0.45 lm PVDF (polyvinylidene fluoride) membrane and collected
into a Costar 3956 96-well plate (Corning, Corning, NY) by centrifugation at
2000 3 g for 5 min. The 96-well plate was sealed with a silicone capmat prior to
LC-MS/MS analysis. Liquid handling during these procedures was accom-
plished using a Hamilton Microlab STAR liquid handling workstation and
Tomtec Quadra 96 320 96-well simultaneous pipetting workstation.
LC-MS/MS analysis. Chromatographic separation of a 10 ll sample
injection volume was accomplished using a Shimadzu binary high-performance
liquid chromatography system (Columbia, MD) incorporating LC-10ADvp
pumps, a CTO-10Avp oven, a Shimadzu HTc 96-well autosampler, and a
Thermo Scientific Hypersil GOLD C18 column (100 3 1.0 mm, 3 lm) with
matching guard and precolumn filter. The mobile phase was initially 70% [60%
0.5mM ammonium acetate (native pH):40% methanol]:30% [20% 0.5mM
ammonium acetate (native pH):80% methanol]. From 2–15 min, the gradient
was ramped to 100% [20% 0.5mM ammonium acetate (native pH):80%
methanol] and then stepped back to initial conditions [60% 0.5mM ammonium
acetate (native pH):40% methanol] over 1 min. The flow rate through the
column was 50 ll/min, and the column was maintained at 35C. The
autosampler was maintained at 4C and rinsed with 1500 ll of 50:50 (vol/vol)
methanol:water after aspiration. Methanol (100%; 10 ll/min) was added as a
postcolumn solvent to the MS. A Thermo Electron TSQ Quantum Discovery
MAX (Thermo Fisher Scientific) with an Ion Max ESI source in negative ion
electrospray ionization mode was used for tandem mass spectrometry. The scan
type was selected reaction monitoring. The transitions monitored at unit
resolution are listed in Table 1.
Initial uptake of [14C]CDCA and [3H]TCA in WT rat suspended
hepatocytes. The initial uptake of substrate (0.5lM unlabeled CDCA plus
0.5lM [14C]CDCA, 25 nCi/ml, or 1lM TCA plus trace [3H]TCA, 60 nCi/ml)
in WT rat suspended hepatocytes was measured in the presence of vehicle,
10lM TRO, or 50lM MK571 using standard methods (Leslie et al., 2007) with
modifications. Uptake was performed in Naþ-containing buffer to measure total
uptake (Naþ-dependent and Naþ-independent) and in Naþ-free choline-
containing buffer to measure Naþ-independent uptake. Naþ-dependent uptake
was calculated as the difference in uptake between the two conditions. The
viability of freshly isolated hepatocytes was >90% as measured by trypan blue
exclusion. Briefly, cells were washed 23 in ice-cold buffer containing sodium
chloride or in buffer in which choline chloride was substituted for sodium
chloride (137mM NaCl or choline chloride, 0.8mM MgSO4, 10mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 1.2mM CaSO4,
0.86mM K2HPO4, 0.14mM KH2PO4, and 5mM glucose, pH 7.4). Cells were
resuspended at 1.0 3 106 cells/ml in the same buffer and kept on ice for
immediate use. Aliquots of cells (4 ml) in bottom-inverted Erlenmeyer flasks
were preincubated at 37C in a shaking water bath for 5 min. Vehicle (0.3%
DMSO), 10lM TRO, or 50lM MK571 was added 15 s prior to the addition of
[14C]CDCA or [3H]TCA. At 15, 30, and 45 s, 200 ll samples of the cell
suspension were removed, placed in a 0.4 ml polyethylene tube over a top layer
of silicone oil:mineral oil (82:18 [vol/vol], 100 ll) and a bottom layer of 3M
KOH (50 ll), and immediately centrifuged. Radioactivity in the cell pellet and
in the supernatant was measured by liquid scintillation counting. Adherent fluid
volume was determined by incubating cells with [14C]inulin (60 nCi/ml) using
the method of Baur et al. (1975). Uptake was normalized to protein
concentrations in the incubation mixtures as measured at the end of each
experiment using the BCA assay (Pierce Biotechnology, Inc., Rockford, IL).
Data analysis. The biliary excretion index (BEI), which represents
the percentage of accumulated substrate that is excreted into bile canaliculi,
TABLE 1
Transitions Monitored at Unit Resolution for LC-MS/MS Analysis of Parent CDCA and Taurine- and Glycine-Conjugated
CDCA Metabolites in Cell Lysates from WT Rat SCH Following a 10-min Incubation with 1mM CDCA
Analyte Molecular weight Salt Retention time (min) Precursor m/z Product m/z Calibration curve range
TCA 515.7 None 5.7 514 124 n/a
d4-TCA 519.7 None 5.7 514 124 Internal standard
d8-TCA 545.73 Na
þ 5.7 522 128 0.5–200 pmol per well
GCA 465.62 None 5.8 464 74 n/a
d4-GCA 469.65 None 5.8 468 74 0.5–100 pmol per well
TCDCA 499.7 None 8.1 498 80 n/a
d4-TCDCA 503.73 None 8.1 502 80 0.5–100 pmol per well
GCDCA 449.62 None 8.1 448 74 n/a
d4-GCDCA 453.65 None 8.1 452 74 0.5–100 pmol per well
CDCA 392.57 None 10.2 5–1000 pmol per well
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was calculated using B-CLEAR technology (Qualyst, Inc., Durham, NC)
from the following equation: BEI ¼ [(Accumulationstandard bufferAccumu-
lationCalcium-free buffer)/Accumulation standard buffer] 3 100% (Liu et al., 1999).
Statistical analysis (one-way ANOVA and Dunnett’s multiple comparison test
or two-way ANOVA with Bonferroni’s multiple comparison test) was
performed using GraphPad Prism 5.03. In all cases, a p value <0.05 was
considered statistically significant.
RESULTS
Accumulation of [14C]CDCA Species in WT and TR Rat
SCH
Accumulation of [14C]CDCA species in cells þ bile and
cells was compared in WT and TR rat SCH, respectively,
following a 10-min coincubation with 1.2lM [14C]CDCA and
vehicle control (CTL), increasing concentrations of TRO (1–
100lM) or 50lM MK571. In WT rat SCH, 1 and 10lM TRO
had no significant effect on accumulation of [14C]CDCA
species in cells þ bile or cells compared with CTL, but 100lM
TRO significantly decreased cell þ bile accumulation,
increased cellular accumulation nearly twofold compared with
CTL, and markedly inhibited the biliary excretion of
[14C]CDCA species; the BEI was reduced from ~60 to 3%
(Fig. 1). MK571 completely inhibited the biliary excretion and
significantly increased cellular accumulation of [14C]CDCA
species 2.8-fold over CTL.
Accumulation of [14C]CDCA species and [3H]TCA also was
measured in TR rat SCH to determine whether loss of Mrp2
altered the biliary excretion of [14C]CDCA species. Accumu-
lation of [14C]CDCA species in CTL TR cells þ bile and cells
(Fig. 2) was similar to WT CTL values (Fig. 1). TRO (10 and
100lM) significantly decreased cells þ bile accumulation of
[14C]CDCA species. Cellular accumulation of [14C]CDCA
species was notably increased over CTL in the presence of
100lMTRO and 50lM MK571, and BEI values decreased
from ~56 in CTL to ~6% and ~10%, respectively, consistent
with inhibition of the biliary excretion of [14C]CDCA species.
For comparison, TCA accumulation also was measured in TR
SCH (Fig. 3). [3H]TCA accumulation in CTL cells þ bile
was ~8.5-fold lower than the accumulation of [14C]CDCA
species in cells þ bile of TR rat SCH, similar to differences in
[14C]CDCA accumulation (Fig. 1) and [3H]TCA accumulation
published previously (Marion et al., 2007) in WT rat SCH. In
contrast to [14C]CDCA species, both 10 and 100lM TRO, as
well as 50lM MK571, significantly decreased cells þ bile
accumulation of [3H]TCA; although there was a trend toward
decreased cellular accumulation of TCA in TR rat SCH, the
differences were not statistically significant.
The BEI of [14C]CDCA species was similar between control
WT and TR rat SCH, and TRO decreased the BEI of
FIG. 1. Accumulation of [14C]CDCA species in cells þ bile (black bars) or
cells (white bars) in WT rat SCH following a 10-min incubation with 1lM
[14C]CDCA or vehicle control (0.1% DMSO; CTL), 1, 10, or 100lM TRO, or
50lM MK571. The BEI was calculated as described in ‘‘Materials and Methods’’
section. Data represent the mean ± SE of triplicate determinations in at least n¼ 3
livers; *p < 0.05 versus CTL cells þ bile; **p < 0.05 versus CTL cells.
FIG. 2. Accumulation of [14C]CDCA species in cells þ bile (black bars) or
cells (white bars) in TR rat SCH following a 10-min incubation with 1.2lM
[14C]CDCA or vehicle control (0.1% DMSO; CTL), 1, 10, or 100lM TRO, or
50lM MK571. The BEI was calculated as described in ‘‘Materials and
Methods’’ section. Data represent the mean ± SE of triplicate determinations in
at least n ¼ 3 livers; *p < 0.05 versus CTL cells þ bile; **p < 0.05 versus CTL
cells.
FIG. 3. Accumulation of [3H]TCA in cells þ bile (black bars) or cells
(white bars) in TR rat SCH following a 10-min incubation with 1lM [3H]TCA
or vehicle control (0.1% DMSO; CTL), 1, 10, or 100lM TRO, or 50lM
MK571. The BEI was calculated as described in ‘‘Materials and Methods’’
section. Data represent the mean ± SE of triplicate determinations in at least n ¼
3 livers; *p < 0.05 versus CTL cells þ bile; **p < 0.05 versus CTL cells.
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[14C]CDCA species in a concentration-dependent manner.
Although MK571 ablated the biliary excretion of [14C]CDCA
in WT cells, the effect in TR rat SCH was not as pronounced.
BEI values for [3H]TCA in TR rat SCH also were decreased by
TRO and MK571, but the decreases in BEI observed with 100lM
TRO and MK571 for [3H]TCA were less than the decreases in
BEI for [14C]CDCA species at the same concentrations.
MK571-Mediated Inhibition of [3H]TCA Accumulation Is
Concentration Dependent
MK571 significantly inhibited [3H]TCA accumulation in
cells þ bile in WT rat SCH in a concentration-dependent
manner (Fig. 4), and there was a clear trend toward increased
cellular accumulation of [3H]TCA with increasing MK571
concentration. The BEI of [3H]TCA also was decreased in a
concentration-dependent manner; 50lM MK571 completely
ablated biliary excretion of [3H]TCA in WT rat SCH.
Accumulation of [14C]CDCA Species and [3H]TCA Is
Temperature Dependent
The accumulation of [14C]CDCA species and [3H]TCA was
measured at 4C in WT rat SCH in order to rule out passive
uptake. As expected, the uptake of [14C]CDCA species and
[3H]TCA into cells þ bile and cells was almost entirely ablated
at 4C, and biliary excretion was negligible, consistent with
temperature-dependent active transport processes for both BAs
(data not shown).
Unconjugated CDCA Is Metabolized in WT Rat SCH
In order to determine the extent of CDCA metabolism during
the 10-min incubation period in the accumulation studies, BAs
were measured by LC-MS/MS in rat SCH incubated with
vehicle (0.1% DMSO; CTL) or 1lM unlabeled CDCA; results
are shown in Figure 5. Analysis revealed that endogenous
unconjugated CDCA was below the limit of quantification in
both cells þ bile and cells in CTL SCH. In CTL cells, modest
amounts of endogenous TCDCA (6% of total) and small
amounts of GCDCA and GMCA (1 and 3% of total,
respectively) were measured, whereas TMCA was the most
abundant BA measured (90% of total) (Table 2). TMCA was
excreted extensively into bile (86% of total), whereas TCDCA
was excreted into bile to a lesser extent (11% of total); GCDCA
and GMCA accounted for 1 and 2%, respectively, of the BAs
in bile (Table 2).
Following a 10-min incubation of WT rat SCH with
exogenously administered CDCA, unconjugated CDCA accu-
mulated in cells; cellular TCDCA increased ~15-fold, GCDCA
increased ~14-fold, and GMCA increased approximately
threefold compared with CTL values (Fig. 5). Biliary excretion
of CDCA and GMCA in the bile of cells exposed to exogenous
CDCA was negligible, whereas TCDCA in bile increased
approximately fourfold. Interestingly, although cells þ bile
accumulation of TMCA did not change between CTL and
treated cells, cellular accumulation increased approximately
twofold and accumulation in bile decreased 21%. Overall,
following the 10-min incubation, the accumulation in cells þ
bile of exogenously administered unlabeled CDCA including
its conjugates (the difference in total BAs before and after
exogenous CDCA exposure) was about 322 pmol/mg protein,
which is consistent with the accumulation of [14C]CDCA
species in cells þ bile in WT CTL SCH (~325 pmol/mg
protein, Fig. 1). This indicates that the CDCA species detected
by LC-MS/MS represent the majority, if not all, of the parent
and metabolites. As summarized in Table 2, following
FIG. 4. Accumulation of [3H]TCA in cells þ bile (black bars) or cells
(white bars) in WT rat SCH following a 10-min incubation with 1lM [3H]TCA
and vehicle control (0.1% DMSO; CTL) or 10, 20, or 50lM MK571. The BEI
was calculated as described in the ‘‘Materials and Methods’’ section. Data
represent the mean ± SE of triplicate determinations in n ¼ 3 livers; *p < 0.05
versus CTL.
FIG. 5. Parent CDCA and formed CDCA species (taurine- and glycine-
conjugated CDCA), TMCA, and GMCA in cells þ bile (solid bars) and cells
(white bars) of WT rat SCH following a 10-min incubation with vehicle (0.1%
DMSO; CTL) or 1lM unlabeled CDCA. Data represent the mean ± SD of
triplicate determinations in n ¼ 1 liver.
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exogenous exposure to CDCA, the amount of TCDCA,
GCDCA, and unconjugated CDCA increased as a percentage
of the total BAs measured in cells and bile, whereas the
percentage of TMCA within the cells and bile decreased as a
percentage of the total; only modest changes in GMCA were
noted.
Initial Uptake of [14C]CDCA Is Primarily Naþ-Independent,
Whereas [3H]TCA Uptake Is Primarily Naþ-Dependent
Initial uptake of [14C]CDCA and [3H]TCA was measured in
WT rat suspended hepatocytes at 15, 30, and 45 s (Fig. 6). Pilot
studies indicated that uptake of both BAs was linear through 90
s (data not shown). TRO and MK571 significantly inhibited
total [14C]CDCA uptake to a similar extent when compared
with CTL (Fig. 6A). Naþ-independent uptake of [14C]CDCA at
45 s in CTL cells (Fig. 6B) was 65 ± 5% of total uptake of
[14C]CDCA at 45 s in CTL cells in the presence of Naþ (set at
100%; Fig. 6A) and was double the Naþ-independent uptake of
[3H]TCA at 45 s in CTL cells (Fig. 6E). Both TRO and MK571
significantly inhibited Naþ-independent [14C]CDCA uptake
(Fig. 6B); Naþ-dependent uptake (Fig. 6C) also was inhibited.
For comparison, initial uptake of [3H]TCA was measured
under the same conditions as [14C]CDCA. TRO and MK571
significantly inhibited total [3H]TCA uptake to a similar extent
at all time points (Fig. 6D). Naþ-independent uptake of
[3H]TCA at 45 s in CTL cells (Fig. 6E) was 34 ± 12% of total
[3H]TCA uptake at 45 s in CTL cells (set at 100%; Fig. 6D),
consistent with previous reports demonstrating that TCA
uptake in rat hepatocytes is mediated primarily by a Naþ-
dependent process (Kemp et al., 2005; Van Dyke et al., 1982).
Both TRO and MK571 significantly inhibited Naþ-independ-
ent [3H]TCA uptake at 45 s (Fig. 6E) and also inhibited Naþ-
dependent [3H]TCA uptake (Fig. 6F).
DISCUSSION
Inhibition of BA transport, which may cause toxic intracel-
lular accumulation of BAs, is one hypothesized mechanism of
TRO toxicity. Although a number of in vivo and in vitro studies
have reported that TRO inhibits transport of the prototypic BA
TCA, the present study demonstrates that TRO differentially
affects the disposition of BAs, specifically CDCA and TCA, in
primary rat hepatocytes following acute exposure. The accumu-
lation of [14C]CDCA in cells þ bile in WT rat SCH was
approximately sixfold higher than accumulation of [3H]TCA in
cells þ bile [historically ~40 to 70 pmol/mg protein (Lee et al.,
2010; McRae et al., 2006; Wolf et al., 2010)]. This is consistent
with previously published data indicating that the rate of uptake
of CDCA in suspended rat hepatocytes was ~10-fold higher than
of TCA (Iga and Klaassen, 1982). In contrast to reports using
[3H]TCA as a model substrate (Ansede et al., 2010; Kemp et al.,
2005; Marion et al., 2007), exposure to 1 or 10lM TRO did not
significantly decrease accumulation of [14C]CDCA species in
cells þ bile or in cells. In fact, treatment with 100lM TRO
significantly increased intracellular accumulation and com-
pletely ablated the biliary excretion of [14C]CDCA species.
These results are significant because they are the first to
demonstrate that TRO causes intracellular accumulation of a
BA species in hepatocytes in vitro without uncoupling uptake
from efflux, as discussed below.
MK571 also inhibited biliary excretion and caused signifi-
cant cellular accumulation of [14C]CDCA species. Hepatic
MRP3/Mrp3 and MRP4/Mrp4 are upregulated under choles-
tatic conditions in both rat (Denk et al., 2004; Donner and
Keppler, 2001) and human (Gradhand et al., 2008; Scheffer
et al., 2002) liver, and are postulated compensatory routes for
basolateral BA efflux. MK571 was expected to increase
intracellular [14C]CDCA accumulation by inhibiting baso-
lateral efflux via Mrps; complete ablation of biliary excretion
was not anticipated because Bsep is responsible for trans-
porting both conjugated and unconjugated BAs into bile, and
MK571 has not been reported to inhibit Bsep. In contrast to
Bsep, which transports monovalent BAs, Mrp2 transports
sulfate- and glucuronide-conjugated (divalent) BAs (Konig
et al., 1999). Impaired biliary excretion of [14C]CDCA by
MK571 suggested that unconjugated [14C]CDCA may be
metabolized completely to an Mrp2 substrate (i.e., sulfate or
glucuronide conjugate) during the 10-min incubation, or that
MK571 inhibited Bsep-mediated biliary excretion of
[14C]CDCA species in rat SCH.
Mrp2-deficient TR rat hepatocytes were utilized to
elucidate a potential role for Mrp2 in the transport of
[14C]CDCA species, and to compare the effect of MK571 on
transport of [14C]CDCA species versus [3H]TCA. Accumu-
lation of [14C]CDCA species in cells þ bile and cells, and the
BEI, were similar in vehicle-treated TR compared with WT
rat SCH, indicating that the lack of Mrp2 did not affect the
disposition of [14C]CDCA species in rat SCH. Furthermore,
MK571 and TRO had similar effects on intracellular
accumulation of [14C]CDCA species in WT and TR rat
SCH. These data suggest that CDCA and/or CDCA metabolites
TABLE 2
Accumulation (% Total) of CDCA, TCDCA, GCDCA, TMCA,
and GMCA in Cells and Bile of Rat SCH Following a 10-Min




Cells Bile Cells Bile
CDCA 0 0 22 4
TCDCA 6 11 21 34
GCDCA 1 1 5 6
TMCA 90 86 50 54
GMCA 3 2 2 2
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are Bsep substrates and that MK571 inhibited Bsep-mediated
biliary excretion.
In rats, ~95 to 98% of BAs are conjugated to taurine, and the
remainder to glycine, whereas in humans, 75% of BAs are
conjugated to glycine and 25% to taurine (Alvaro et al., 1986);
conjugation increases aqueous solubility, facilitating biliary
excretion (Kullak-Ublick et al., 2004). LC-MS/MS analysis
revealed that when CDCA was administered exogenously to
SCH, unconjugated CDCA, TCDCA, and GCDCA increased
within the cells during the 10-min incubation. Of the total BAs
in bile following exposure to CDCA, 88% of total biliary BAs
were conjugated to taurine, 8% were conjugated to glycine, and
4% remained as unconjugated CDCA (Table 2). The present
results are consistent with data from Hoffman et al. (1975),
showing that when unconjugated CDCA was injected into rats,
>90% was excreted into the bile as the taurine conjugate, <5%
as unconjugated CDCA, and a small amount was excreted as
the glycine conjugate (Hoffman et al., 1975). Both TRO and
MK571 increased cellular accumulation of [14C]CDCA species
in WT and TR rat SCH; these results raise the possibility that
in humans, TRO may cause intracellular accumulation of
CDCA/CDCA species. GCDCA, in particular, is cytotoxic and
has been shown to induce apoptosis in primary rat hepatocytes
(Kaplowitz and DeLeve, 2003).
Several studies have shown that TRO inhibits uptake and
biliary excretion of TCA in rat (Ansede et al., 2010; Kemp
et al., 2005; Marion et al., 2007) and human (Marion et al.,
2007) suspended hepatocytes and SCH, leading to unchanged
or decreased intracellular accumulation. Consistent with these
reports, in the present studies, 10 and 100lM TRO
significantly decreased accumulation of [3H]TCA in cells þ
bile of TR rat SCH, but had no significant effect on cellular
FIG. 6. Accumulation of [14C]CDCA (A, B, and C) or [3H]TCA (D, E, and F) in suspended rat hepatocytes in the presence of 1lM [14C]CDCA or 1lM
[3H]TCA and vehicle (d,s 0.3% DMSO; CTL), 10lM TRO (n,h), or 50lM MK571 (:,n). Lines represent the linear regression of the data using GraphPad Prism
5.03. Total accumulation (Naþ-dependent and independent) was measured in Naþ-containing buffer (A and D). Naþ-independent uptake was measured in choline-
containing buffer (B and E). Naþ-dependent uptake was calculated by subtracting Naþ-independent accumulation from total accumulation (C and F; open symbols
and dashed lines). Data represent the mean ± SE of triplicate determinations in n ¼ 3 experiments; †p < 0.05 versus CTL for TRO, and ‡p < 0.05 versus CTL for
MK571.
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accumulation. In contrast, Jemnitz et al. (2010) used the
method of Lengyel et al. (2008) to assess the effects of TRO on
basolateral and canalicular efflux of TCA in SCH. In these
studies, [3H]TCA was preloaded into rat and human SCH by
incubating them with [3H]TCA in the absence of inhibitor;
then, [3H]TCA was washed off, and cells were incubated with
various inhibitors or vehicle in standard HBSS or in Ca2þ- and
Mg2þ-free HBSS buffer. At the end of the 10-min incubation,
effluxed [3H]TCA was measured in the buffer and in cells þ
bile or in cells. Using this method, 100lM TRO decreased
biliary excretion and increased intracellular accumulation of
[3H]TCA in both rat and human SCH without affecting
basolateral efflux of [3H]TCA into the medium. These results
established that TRO can cause the intracellular accumulation
of TCA, which had not been shown using other methods in
SCH. By preloading hepatocytes with TCA, any inhibitory
effects of TRO on BA uptake were bypassed. However, this
paradigm, which uncouples the uptake and efflux of BAs, does
not realistically represent the in vivo situation. The intracellular
accumulation of a substrate in hepatocytes is dependent upon
both uptake and efflux processes. BAs are highly conserved
through enterohepatic cycling; basolateral reuptake of BAs
from the blood greatly exceeds BA synthesis, and intracellular
BAs are excreted rapidly into the bile canaliculi. This vectorial
transport of BAs from blood to bile represents the normal
circulation of BAs. In previous studies using TCA to examine
the disposition of BAs following TRO exposure, it appears that
TRO-mediated inhibition of [3H]TCA uptake precluded any
effects on intracellular [3H]TCA accumulation (Ansede et al.,
2010; Kemp et al., 2005; Marion et al., 2007).
Suspended rat hepatocytes were utilized to examine the
effects of TRO on the uptake of CDCA versus TCA. In
previous studies, TRO inhibited TCA uptake in suspended rat
(Kemp et al., 2005) and human (Marion et al., 2007)
hepatocytes and in basolateral membrane vesicles (Snow and
Moseley, 2006). Based on results in SCH, TRO and MK571
were expected to have little, if any, effect on initial uptake of
CDCA in suspended rat hepatocytes. The uptake of CDCA
reportedly occurs partially by a nonsaturable Naþ-independent
mechanism, hypothesized to be passive diffusion, and partially
by a saturable process (Bartholomew and Billing, 1983; Iga
and Klaassen, 1982; Van Dyke et al., 1982). In cultured rat
hepatocytes, uptake of CDCA was significantly, but not
completely, reduced by the removal of Naþ and also by
ouabain, a Naþ-Kþ-ATPase inhibitor (Van Dyke et al., 1982),
suggesting a Naþ-dependent component of uptake (i.e., Ntcp).
Results of the present studies confirmed that the majority of
[3H]TCA uptake was Naþ-dependent, whereas [14C]CDCA
uptake was primarily Naþ-independent. Surprisingly, both
TRO and MK571 decreased Naþ-dependent and Naþ-
independent initial uptake of [14C]CDCA. MK571 reportedly
inhibits OATP1B3 (Letschert et al. 2005) and OATP2B1
(Letschert et al., 2006), which would explain inhibition of the
Naþ-independent component of CDCA uptake. MK571 also
inhibited Naþ-dependent TCA uptake into hepatocytes. To our
knowledge, there are no prior reports of MK571-mediated
inhibition of NTCP/Ntcp.
Decreased initial uptake of [14C]CDCA in suspended rat
hepatocytes is compatible with results in SCH. Given that total
intracellular accumulation of BAs is dependent on uptake
processes as well as canalicular and basolateral efflux
processes, then total accumulation of [14C]CDCA species in
cells in the presence of 10lM TRO may be the result of
decreased uptake coupled with decreased efflux, resulting in no
change in net accumulation relative to CTL. However, the
increased intracellular [14C]CDCA accumulation with 100lM
TRO may indicate that higher concentrations of TRO inhibit
biliary excretion of [14C]CDCA to a greater extent than uptake.
Thus, TRO may have different effects on uptake and efflux
depending on the concentration at the site of transport.
In conclusion, TRO differentially affected the uptake and
accumulation of CDCA species compared with TCA in rat
SCH, causing an intracellular increase in CDCA species but
not TCA. This supports the hypothesis that impaired BA
transport is a potential mechanism of TRO hepatotoxicity. In
addition to the known inhibitory effect of MK571 on MRPs,
our results suggest that MK571 also inhibited Ntcp and Bsep.
Overall, these results demonstrate that inhibitors of BA
transport proteins may have differential effects on the
disposition of individual BAs and suggest that use of a single
BA substrate for transport studies (i.e., TCA) may yield an
incomplete picture of a compound’s effects on overall BA
disposition. Therefore, multiple BA species should be
evaluated as more cytotoxic BAs may accumulate in
hepatocytes, potentially contributing to toxicity.
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